A phase II study of gemcitabine at fixed infusion rate of 10 mg/m 2/min with or without immunotherapy in advanced renal cancer

Fable Zustovich, Giuseppe Cartei, Davide Pastorelli, Ornella Nicoletto, Fedra Gottardo, Luca De Zorzi, Massimo Dal Bianco

Research output: Contribution to journalArticle

Abstract

Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m2/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor.

Original languageEnglish
Pages (from-to)4461-4464
Number of pages4
JournalAnticancer Research
Volume27
Issue number6 C
Publication statusPublished - Nov 2007

    Fingerprint

Keywords

  • Gemcitabine
  • Immunotherapy
  • Kidney cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zustovich, F., Cartei, G., Pastorelli, D., Nicoletto, O., Gottardo, F., De Zorzi, L., & Dal Bianco, M. (2007). A phase II study of gemcitabine at fixed infusion rate of 10 mg/m 2/min with or without immunotherapy in advanced renal cancer. Anticancer Research, 27(6 C), 4461-4464.